Epstein-Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes \textit{in vitro}

Elliott D. SoRelle$^{1,2}$*, Nicolás M. Reinoso-Vizcaino$^{3,4}$*, Gillian Q. Horn$^3$ and Micah A. Luftig$^3$

$^1$Department of Molecular Genetics & Microbiology, Duke University, Durham, NC, United States, $^2$Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, United States, $^3$Department of Immunology, Duke University, Durham, NC, United States

Human B cells encompass functionally diverse lineages and phenotypic states that contribute to protective as well as pathogenic responses. Epstein-Barr virus (EBV) provides a unique lens for studying heterogeneous B cell responses, given its adaptation to manipulate intrinsic cell programming. EBV promotes the activation, proliferation, and eventual outgrowth of host B cells as immortalized lymphoblastoid cell lines (LCLs) \textit{in vitro}, which provide a foundational model of viral latency and lymphomagenesis. Although cellular responses and outcomes of infection can vary significantly within populations, investigations that capture genome-wide perspectives of this variation at single-cell resolution are in nascent stages. We have recently used single-cell approaches to identify EBV-mediated B cell heterogeneity in \textit{de novo} infection and within LCLs, underscoring the dynamic and complex qualities of latent infection rather than a singular, static infection state. Here, we expand upon these findings with functional characterizations of EBV-induced dynamic phenotypes that mimic B cell immune responses. We found that distinct subpopulations isolated from LCLs could completely reconstitute the full phenotypic spectrum of their parental lines. In conjunction with conserved patterns of cell state diversity identified within scRNA-seq data, these data support a model in which EBV continuously drives recurrent B cell entry, progression through, and egress from the Germinal Center (GC) reaction. This “perpetual GC” also generates tangent cell fate trajectories including terminal plasmablast differentiation, which constitutes a replicative cul-de-sac for EBV from which lytic reactivation provides escape. Furthermore, we found that both established EBV latency and \textit{de novo} infection support the development of cells with features of atypical memory B cells, which have been broadly associated with autoimmune disorders. Treatment of LCLs with TLR7 agonist or IL-21 was sufficient to generate an increased frequency of IgD-/-CD27-/-CD23-/-CD38+/CD138+ plasmablasts. Separately, \textit{de novo} EBV infection led to the development of CXCR3+/-CD11c+/-FCRL4+ B cells within days, providing evidence for possible T cell-independent origins of a recently described EBV-associated neuroinvasive CXCR3+ B cell subset in patients with multiple sclerosis. Collectively, this work reveals unexpected virus-
driven complexity across infected cell populations and highlights potential roles of EBV in mediating or priming foundational aspects of virus-associated immune cell dysfunction in disease.

KEYWORDS
Epstein-Barr virus, B cell, germinal center, single-cell, lymphoblastoid cells, autoimmunity, chronic infection, atypical memory B cells

Introduction

The widespread utilization of single-cell RNA sequencing (scRNA-seq) has generated new high-dimensional perspectives on the diversity of the human B cell repertoire. Recent scRNA-seq studies have revealed that extensive heterogeneity and dynamic complexity are core aspects of B cell development and clonal selection (1–4), tissue-specific distributions (5), dysregulation in lymphoma (6–9), pathogenicity in autoimmune disorders (10–12), and responses to antigen (13, 14) and infection (15, 16). Separately, advances in classic single-cell methods including flow cytometry and cell sorting (17) provide flexible workflows to validate and isolate cell subsets identified from scRNA-seq experiments and support subsequent investigations. Used in conjunction, this battery of techniques supports genome-wide profiling and niche-specific functional studies of cell behaviors and responses to stimuli. Each of these capabilities are essential to resolve the broad landscape of B cell mediated immunity, including how it is reshaped across a spectrum of diseases to the point of pathogenic dysregulation.

Arguably, the pathogen most intricately interwoven with B cell epigenomic programming and immune responses in humans is infection with Epstein-Barr Virus (EBV), a gammaherpesvirus found in approximately 95% of adults worldwide (18). The EBV virion consists of a 172 kB dsDNA genome encapsulated by an icosahedral glycoprotein capsid with associated tegument proteins. Viral particles are transmitted between hosts through saliva, from which the virus can infect oral epithelial cells, traverse the oral mucosa, and eventually encounter host B cells resident within tonsillar lymphoid tissue (18). Binding of the viral capsid glycoprotein gp350 to an extracellular domain of cell surface-expressed CR2 (CD21) facilitates viral entry through endocytosis (19–21). Internalized virions then translocate to the nucleus, where the linear viral genome is deposited and rapidly circularizes to form an extrachromosomal episome (22, 23). Successful infection is achieved through the sequential expression of six EBV nuclear antigens (EBNAs) and two latent membrane proteins (LMPs) in distinct programs that co-opt B cell immune response dynamics (24). In the pre-latent phase, EBNA2 and EBNA-LP are expressed and co-transactivate host genes involved in cell activation and proliferation (25–29). EBNA2 further transactivates viral C promoter expression of EBNA1 (30), which tethers the viral episome to host chromatin (31), and EBNA3A–C, which have diverse roles including suppression of apoptosis and modulation of cell proliferation to avoid growth-associated DNA damage induction (32–40). The resulting stage – Latency IIb – is defined by rapid division of host B cells that resembles germinal center (GC) dark zone (DZ) proliferation conventionally induced by B Cell Receptor (BCR) cognate antigen binding (41–44). EBNA2 further transactivates the expression of viral LMP1 and LMP2A/B (45, 46), yielding the Latency III program in which all EBNAs and LMPs are expressed simultaneously. This stage of infection reflects the phenotype of GC Light Zone (LZ) B cells through LMP1-mediated stimulation of pro-survival NF-κB pathway signaling (47–50) and LMP2A-mediated evasion of T cell surveillance and mimicry of an activated BCR (51–55). Infected B cells that successfully navigate the GC reaction eventually exit as effector B cell types, with progression to memory B cells (MBCs) providing the route to a lifelong reservoir for latent EBV persistence (56–58). Alternatively, host cell GC exit and differentiation to plasmablasts constitutes a host cell fate that precludes persistent latency. To bias GC output toward MBC formation, EBNA3A and EBNA3C mediate epigenetic suppression of the host gene PRDM1, inhibiting plasma differentiation (59). In the event that this suppression is unsuccessful, EBV can escape terminally differentiated plasma cells through activation of lytic replication (60). The protein encoded by the BZLF1 gene orchestrates this phase, and its expression is transactivated by the host transcription factor XBP1 expressed in antibody-secreting cells (ASCs) (61–64). Lytic reactivation from plasma cells thus leads to amplified EBV virion formation and transmission to subsequent hosts.

EBV co-evolution with host B cells has yielded intimate viral adaptations to achieve lifelong latency in a subset of MBCs within virtually every infected person. Although benign in most cases, EBV infection of this cellular niche entails widespread viral association – and often etiological involvement – with lymphoproliferative diseases (65, 66). Indeed, EBV was first
isolated from biopsies of endemic Burkitt Lymphoma (eBL) from pediatric patients (67), and the virus is known to be an essential etiologic factor in eBL development (68–70). EBV is also a major contributing factor to lymphomagenesis in the context of immune suppression. Virtually all instances of Hodgkin’s Disease and Primary CNS Lymphoma (PCNSL) in HIV-infected individuals are EBV-driven (71, 72), as are 90–100% of AIDS-related Primary Effusion Lymphomas (PEL) (73) and the immunoblastic subtype Diffuse Large B Cell Lymphoma (DLBCL) (74). Likewise, the virus is a crucial driver of post-transplant lymphoproliferative disease (PTLD, a DLBCL subset) in organ transplant recipients (75), as the requisite immunosuppressive regimens can ablate T cell-mediated restraint of EBV+ MBC clones (76). Collectively, EBV is associated with 1.5% of all cancer cases diagnosed annually (77), including non-B cell malignancies such as Nasopharyngeal Carcinoma (NPC) (68, 78) and nearly 10% of gastric cancers (79).

Associations of EBV with numerous diseases of immune impairment and autoimmunity have also been identified. These include systemic lupus erythematosus (SLE) (80–84), rheumatoid arthritis (RA) (85–89), myasthenia gravis (MG) (90), primary Sjogren’s Syndrome (pSS) (91, 92), and co-pathogenicity in chronic HIV and Plasmodium falciparum infections (78, 93). Hypothesized etiologic involvement of EBV in the development of multiple sclerosis (MS) (94, 95) has also been substantiated through recent epidemiologic and mechanistic studies (96, 97). Despite the observed viral associations, the functional roles that EBV plays in these illnesses remain incompletely understood. However, it is noteworthy that pathogenic expansion of a particular MBC niche – so-called “atypical” MBCs (atMBCs) – has been identified in many of the same diseases (12, 98–106). Because single-cell methods are well-suited to identify and study specific cellular niches, such approaches may help shed light on the potential significance of EBV infection with atMBCs.

Our lab has long been interested in dissecting the distinct B cell fates that develop following EBV infection (32, 43, 107–110). Recently, we have utilized single-cell sequencing to reveal previously unknown facets of the early stages of infection (15) and an unexpected degree of heterogeneity in virus-immortalized lymphoblastoid cell lines (LCLs) (111), which provide useful in vitro models of EBV+ lymphomas. This report builds upon our previous single-cell study of LCL heterogeneity to dissect the dynamics of virus-driven B cell responses. Through the integration of time-resolved FACS experiments and informatic approaches, we construct a general model of EBV-immortalized B cell dynamics. Our data also highlight potential viral contributions to pathogenic aspects of atMBCs that have described in EBV-associated autoimmune diseases, which we further investigated using LCLs as an initial model system.

Materials and methods

Cell lines

Lymphoblastoid cell lines (LCLs) were generated through de novo infection of human peripheral blood B cells at MOI = 5 with the B95-8 strain of EBV as previously described (32). All cell lines used in this study were cultured in RPMI media supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO₂.

Flow cytometry and sorting

Cells were prepared for flow cytometry experiments by standard washing and staining methods. Briefly, ~2x10⁵ (5) cells were washed via centrifugation for 5 min at 300 x g and resuspended in FACS buffer (1x PBS + 2% heat-inactivated Fetal Bovine Serum, FBS) for each sample of interest. Washed cells were centrifuged again and supernatant was aspirated, after which fluorescent antibody cocktails were added for biomarker staining. After 30 min of antibody incubation in the dark at ambient temperature, stained cells were washed with excess FACS buffer (up to 2 mL), centrifuged, aspirated, and resuspended for flow cytometry and/or fraction sorting. Cytometry data in the absence of sorting were acquired on a BD FACS Canto II analyzer system, and sorting experiments were performed on an Astrios Cell Sorter. Fluorescent antibodies against CD19, IgD, CCR6, CD23 (FCER2), ICAM1, CD27, CD28, CD138 (SDC1), CXCR3, CD11c(ITGAX), FCRL4, and FCRL5 were used for the experiments described herein. These include: αCD19-PE (BioLegend Cat. #302254) and αCD19-PE/Cy7 (BioLegend Cat. #302216), αIgD-PE/Cy5 (BioLegend Cat. #348250), αCCR6-PE (BioLegend Cat. #353410), αCD23-PE/Cy7 (BioLegend Cat. #338516), αICAM1-PacBlue (BioLegend Cat. #322716), αCD27-FITC (BioLegend Cat. #356404), αCD38-APC/Cy7 (BioLegend Cat. #356616), αCD138-PerCP-Cy5.5 (BioLegend Cat. #352310), αCXCR3-APC-Fire810 (BioLegend Cat. #353762), αCD11c-PE/Cy5 (BioLegend Cat. #301610), αFCRL4-PE (BioLegend Cat. #340204), and αFCRL5-APC (BioLegend Cat. #340306).

Single-cell RNA-seq data processing

LCL scRNA-seq data were processed as described previously (111, 112). Briefly, sequencing base calls were used to generate demultiplexed reads (fastq files) via cellranger mkfastq with default QC parameters (CellRanger, 10x Genomics). Reads were aligned against species-concatenated reference genome packages (hg38 + NC_007605) prepared via cellranger mkref. Unique Molecular Identifier (UMI) read count matrices were produced.
from the alignment step (cellranger count). These and other single-cell LCL datasets are publicly available via the NIH Gene Expression Omnibus (GEO, accession GSE158275 and GSE126321). We also incorporated analysis of scRNA-seq data from discarded human tonsils generated in our lab (GSE159674).

Single-cell data analysis and visualization

Count matrices from LCL single-cell experiments were analyzed and visualized in R using Seurat v4 (113–115). Expression counts were normalized, variable features were identified, and the datasets were subsequently integrated through identification of anchor features (SelectIntegrationFeatures(), FindIntegrationAnchors(), and IntegrateData() functions in Seurat). Integrated data were QC-filtered to remove any cells with <200 unique feature RNAs, >65,000 total RNA counts, and/or >10% mitochondrial reads. Next, read data were scaled and analyzed via principal component analysis (PCA). Cell cycle scores were also calculated to assign mitotic phases, but cell cycle regression was not performed during the scaling step. The top PCs (n = 30) were dimensionally reduced via uniform manifold approximation (UMAP) (116) and unsupervised clustering was performed at several resolutions to identify phenotypes and analyze differential gene expression. To correct for read dropout while preserving biological zeros, imputation was performed at several resolutions to identify phenotypes from EBV+ lymphoblastoid cells lines (LCLs), which are in vitro models of B cell lymphomas of the immune suppressed (121). These data revealed an apparent continuum of EBV+ B cell phenotypes ranging from the early stages of cell activation and pro-survival signaling to terminal differentiation into effector memory cells or plasmablasts (Figure 1A). Numerous genes encoding surface-expressed proteins were differentially expressed between these activated and differentiated states. We used these findings to develop a simple FACS approach based on ICAM-1 [highly expressed on LMP-1Hi activated B cells (122)] and CD27 (canonically expressed on antigen-experienced memory B cells) to further investigate LCL heterogeneity. Consistent with single-cell transcriptomic data, LCLs exhibited anticorrelated expression of ICAM-1 and CD27, with ICAM-1Hi/CD27Lo (30-55% of cells on average) providing a proxy for GC light zone (LZ)-like activated B cells and ICAM-1Lo/CD27Hi (5-15% of cells on average) corresponding to differentiated memory B cells (MBCs). The most frequent cell state observed by FACS was an ICAM-1Lo/CD27Lo phenotype (40-60% of cells on average), which was interpreted as one or more transitional states (Figure 1B, S1A). Based on these observations, we used a cell sorting strategy to isolate these three major phenotypes for subsequent analysis (Figure 1C, S1A). Interestingly, the frequencies of each observed fraction were dependent upon cell density and culture conditions. When LCLs were plated at different concentrations in fresh media, both a decrease in ICAM-1Lo/CD27Hi cells and a small (but not statistically significant) increase in the ICAM-1Hi/CD27Lo cell frequency were observed as cell density increased. Bulk populations retained the equilibrium distribution of parental line phenotypes, provided that the cultures were maintained between 3×10^5 - 1x10^6 cells/mL (Figure S1B).
Isolated LCL subpopulations spontaneously re-establish parental line phenotypic heterogeneity in vitro

To better understand the growth dynamics and possible state interconversions among the three identified subpopulations (ICAM-1\(^{Hi}/\)CD27\(^{Lo}\), ICAM-1\(^{Lo}/\)CD27\(^{Hi}\), and ICAM-1\(^{Lo}/\)CD27\(^{Hi}\)), we collected cell counts and time-resolved FACS data for each fraction. Among the three fractions isolated from independent LCLs (n = 3), ICAM-1\(^{Hi}/\)CD27\(^{Lo}\) cells exhibited the fastest growth, followed by ICAM-1\(^{Lo}/\)CD27\(^{Lo}\) cells. The ICAM-1\(^{Lo}/\)CD27\(^{Hi}\) fraction displayed minimal growth over the measurement period. However, all three phenotypes retained long-term viability in culture. These measurements demonstrated the significant growth advantage of EBV\(^{+}\) activated B cells relative to EBV\(^{+}\) differentiated B cells (Figure 2A, S1C, D). Notably, each fraction spontaneously re-established the full ICAM-1/CD27 phenotypic profile displayed by unsorted parental LCLs within several days in culture after sorting (day 0). Thus, dynamic transitions – possibly with conserved rate constants – sustain a core distribution of heterogeneous phenotypes within EBV-infected B cell populations in vitro (Figure 2B, C, S1C, D).

Cyclical dynamics of GC entry, engagement, and exit are conserved across EBV\(^{+}\) LCLs

Based on the observed dynamic heterogeneity, we reanalyzed scRNA-seq data from 3 LCLs representing infection with two EBV strains (B95-8 and M81). We first identified...
gene expression within cell subsets corresponding to the ICAM-1^{Hi}/CD27^{Lo} and ICAM-1^{Lo}/CD27^{Hi} FACS phenotypes across sample-integrated datasets (Figures 3A, B). Based on initial clustering, 18.7% of all sequenced cells corresponded to activated LZ-like B cells (ICAM-1^{Hi}/CD27^{Lo}) in LCLs. 18.0% of cells across LCLs matched the differentiated MBC phenotype (ICAM-1^{Lo}/CD27^{Hi}). These frequencies were approximately similar to those observed in the FACS experiments described previously, with higher frequencies of ICAM-1^{Hi}/CD27^{Lo} cells observed via FACS relative to scRNA-seq. Further, differentially-expressed genes (DEGs) between activated and differentiated states were broadly consistent.
across samples. We further identified clusters that corresponded to transitional states between the activated and differentiated subsets. In contrast to our prior study of LCLs, we did not perform cell cycle marker gene regression during the data scaling step of the scRNA analysis, which preserved a distinct cluster of actively cycling cells. Cells in this cluster expressed numerous cell cycle genes and proliferation markers including \textit{MKI67} and \textit{CDK1} and were further resolved by mitotic phase (S, G2M; Figure S2A). These proliferating cells were consistent with the GC Dark Zone (DZ) state (42, 123). In addition to cycling cells, a cluster of a pre-GC activated precursor to early memory B cells (AP-eMBCs) was also identified based on expression of \textit{CCR6}, \textit{CD22}, and other genes described in prior work (3, 15, 124) (Figure 3C, S2B). The four main phenotypes (MBC, AP-eMBC, DZ, and LZ) accounted for 86.4% of cells across LCL datasets.
Higher resolution clustering further refined cell states by immunoglobulin heavy chain class and cell cycle phase, for which we calculated pseudotime trajectories. Pseudotime graphs rooted within G1-phase differentiated memory cell clusters supported cyclical progression through the early stages of B cell activation, GC reaction (e.g., DZ—→LZ transitions), and eventual cell cycle exit and return to a G1-phase MBC state or (infrequently) pre-PB generation (Figure 3D). The apparent dynamic qualities of host gene expression were reflected in state-resolved EBV transcriptomes. On the basis of western blotting and qPCR, LCLs are conventionally described as having the latency III EBV program in which all EBNAs and LMPs are simultaneously expressed (24). However, pseudotime-ordered states portrayed a more nuanced picture of viral latency dynamics. As indicated by the fraction of cells expressing a given latency gene in each cluster, very few individual cells within LCLs simultaneously express all latency III genes. Actively dividing cells exhibited the broadest latency gene expression including elevated expression of EBNA1 (from the Q promoter), EBNA2 (from the C promoter), and EBNA-LP. With the notable exception of the small lytic cell population, the highest expression of LMP-1 was observed in the GC LZ-like NF-xB state. Along with EBER1 and EBER2, EBNA3A and EBNA3B expression from the C promoter exhibited transient upregulation in early cell cycle stages followed by decreases in G2M and G0/G1 states (Figure 3E). Collectively, the phenotype dynamics observed by FACS and conserved host and viral transcriptomic diversity led us to propose a model in which EBV infection perpetuates a core loop of host B cell entry, engagement, exit, and re-entry into a GC-like reaction in vitro (Figure 3F). In this model, persistent latent infection continuously drives the machinery of B cell adaptive immune responses in the absence of cognate antigen and restraint by other immune cell types.

To further investigate the extent of EBV-induced GC characteristics in LCLs, we assayed the presence of cells with enriched signatures for distinct GC states based on literature-derived annotation (44, 125–135). By applying this analysis to scRNA-seq data from human tonsil samples as a reference for normal GCs, we confirmed that LCLs contained distinct subpopulations with characteristic of different pre-GC, GC, and post-GC cell states (Figure 4A). Likewise, we observed cells in LCLs with enriched signatures for classically described GC B cell genes and those used for molecular classification of GCB versus ABC DLBCL subtypes (125, 126). Surprisingly, LCL subsets with strong expression of pre-GC mantle zone (MZ) marker genes (CCR6, CD22, CD69, FCRL4, FCRL5, BANK1, MARCH1) had the highest correlation with the canonical GC B cell marker set (BCL6, LMO2, MYBL1, MME, SERPINA9, GCSAM, DGKD, IL4R, SPI1, SH2B2, ALOX5, BCL7A, LCK, OGGI). Moreover, LCLs further exhibited strong correlation of GCB and ABC DLBCL gene sets in contrast to tonsil tissue, which displayed anticorrelation of these sets as expected (Figure S3A). Collectively, these data suggest that the GC-like dynamics observed within LCLs are dysregulated with respect to normal GCs. In a detailed dissection of GM12878, we analyzed key gene expression within the EBV-driven perpetual GC. This analysis supported a potential path of cell state transitions from a mantle zone B cell phenotype through DZ entry, proliferation, LZ entry, LZ exit, and post-GC B cell differentiation, which indicated an apparent IRF4- and PRDM1-associated fate bifurcation between ASC development and GC re-entry via the MZ state (Figure 4B). In another example, we found that hallmark DZ genes (FOXO1, CXCR4) and LZ genes (MYC, CD83) were co-expressed in distinct subsets of GM18502 and that zone-mismatched genes had anticorrelated expression (Figure S3B). LMO2 was generally co-expressed with other GC biomarkers (MYBL1, SERPINA9, ALOX5, LRMP) across tonsils and LCLs, although weaker correlations were observed in LCLs (Figure S3C). Interestingly, GC LZ genes (BATF, CD40, CD83, CD86, CD274 (PD-L1), IFN) were more strongly co-expressed with ICAM1 in LCLs than in tonsils (Figure S3D), suggesting a bias toward LZ-like state enrichment in the context of EBV infection. Pseudotime analysis of classic GC B cell biomarker expression provided further support for EBV-driven GC-like dynamics in LCLs (Figures S3E-L), although we observed the striking absence of BCL6 expression across LCLs (Figure S3M). As EBV has been shown to suppress BCL6 expression and degrade BCL6 protein through EBNA3A, EBNA3C, and viral microRNAs (59, 136), the retention of certain germinal center features in LCLs implicates viral mechanisms that supplant BCL6 transcriptional regulation to some degree.

Infrequent plasmablast formation, cellular quiescence, and viral reactivation define GC-tangent fates

Sequencing data supported multiple possible fates for CD27+ cells within LCLs (Figure S4A). Cells with an expression profile of CCR6+/CD27+/PRDM1+/SDC1- were consistent with B cell re-entry into a GC-like reaction from the AP state. Other subsets expressing combinations of CD27, CD38, and PRDM1 but not CCR6 or SDC1 were consistent with post-GC memory B cells and pre-plasmablasts. Notably, only a subset of post-GC CD27+ cells expressed SDC1/CD138 and other late markers of dedication to the ASC fate. This ASC population and other subsets (typically with extremely high or low viral reads) appeared to exit conserved perpetual GC dynamics, which we characterized as “tangent” fate trajectories (Figure 5A). The terminally differentiated plasmablast tangent was further defined by elevated expression of CD27, CD38, TNFRSF17/BCMA and other genes previously identified from transcriptomic profiling of murine B cell subsets (137) (Figure 5B, top panel). These cells were distinguished by the highest expression of transcription factors (PRDM1, XBP1,
MZB1 known to promote B cell differentiation to plasma cells (138, 139). Intriguingly, EBV+ plasma cells also expressed high levels of interferon response genes including, IFI35, IFITM1, OAS1, MX1, and IFNG-AS1, which enhances IFNG production in NK cells (140), and genes mediating redox stress (TXNIP, TXNDC11, TXNDC15), presumably in response to metabolic burdens associated with antibody secretion (141) (Figure S4B). Another tangent cluster of cells exhibited the fewest total and unique mRNAs but was enriched in transcripts for oxidative stress response genes (111) and ribosome subunit biogenesis (Figure 5B, middle panel). The low overall read counts suggested this cluster contained quiescent or growth-arrested cells, and functional enrichment of the top markers in these cells included ribosomal large subunit biogenesis (GO:0042273, FDR = 9.55e-11); regulation of G2/M phase transition (GO:1902749, FDR = 5.4e-5); hydrogen peroxide metabolism (GO:0042743, FDR = 0.0019); regulation of transcription from RNA Pol II promoter in response to hypoxia (GO:0061418, FDR = 0.0073); and negative regulation of nitrosative stress-induced intrinsic apoptotic signaling (GO:1905259, FDR = 0.039) (Figure S5B). A third distinct tangent fate had clear hallmarks of EBV lytic reactivation including expression of viral immediate (BRLF1), early (BALF1, BARF1), and late (BZLF2, BLLF1) lytic genes (Figure 5B, bottom panel). Consistent with prior reports, lytic
cells within LCLs also displayed elevated expression of LMP1. These reads may have derived from the truncated lytic LMP1 transcript (lyLMP1), which has been shown to be essential for successful virion release in reactivation (142, 143). These cells also expressed host genes (NFATC1, MIER2) known to mediate EBV reactivation (144) as well as several long non-coding RNAs (lncRNAs) and genes involved in chromatin remodeling and epigenetic silencing (HOTAIRM1, REST, MALAT1, ZEB2-ASI, KCNQ1OT1, HOXB-AS3, DNMT3B, HDAC1, HDAC4) (Figure S5).

Atypical MBCs and autoimmune-like responsiveness to IL-21 and TLR7 agonism in EBV+ LCLs

We recently found that EBV infection induced non-canonical gene expression changes within T-bet+ atypical memory B cells (atMBCs) (15), which have been identified as expanded pathogenic cell subsets in diseases including multiple sclerosis (MS) (10), systemic lupus erythematosus (SLE) (12, 145), and rheumatoid arthritis (RA) (146). This atMBC response to infection included upregulation of pro-inflammatory signature and aberrant expression of neuronal lineage genes. Based on these findings from de novo infection, we questioned whether cells consistent with EBV+ atMBCs were present in LCLs. One of the three scRNA-seq datasets from LCLs generated in our lab contained a clear population of atMBCs based on expression of TBX21 (T-bet) and CXCR3 in addition to genes encoding BCR regulating receptors, including FCRL4 and FCRL5 (Figures 6A, S6A) (147, 148). Notably, these EBV+ atMBCs were highly correlated with genes defining the pre-GC activated B cell precursor to MBC (AP-eMBC) state (CCR6, POU2AF1, CD22). EBV+ atMBCs were further distinguished by elevated expression of genes encoding receptors for key cytokines (IL21R, IFNGR1) and innate stimuli (TLR7 and its downstream signaling adapter gene MYD88) known to mediate atMBC differentiation, including pathogenic responses in numerous human autoimmune diseases (Figure 6B) (100, 104, 149). Re-analysis of publicly available data from two additional LCLs (GM12878 and GM18502) likewise revealed conserved co-expression of IL21R, IFNGR1, TLR7, CCR6, CD22, FCRL5, TBX21, CXC3, and CD11c/ITGAX, indicating the presence of EBV+ atMBC/AP-eMBC populations in three of five analyzed LCLs (Figure S6B).

TLR7 agonism and IL-21 treatment have been shown to elicit expansion and differentiation of human T-bet+ atMBCs in vitro and analogous murine age-associated B cells (ABCs) in vivo (100, 149). Given these findings, we hypothesized that EBV+ atMBCs might exhibit similar responses upon stimulation (Figure 6C). To test this, we treated LCLs with the TLR7 agonist R848 (resiquimod, 2 μg/mL), IL-21 (10 ng/mL), or both and measured cell growth and surface marker expression relative to a control treatment (0.2% DMSO). Despite having a

FIGURE 5
Plasma cell differentiation, growth arrest and quiescence, and viral reactivation define tangent fate trajectories arising from core GC dynamics. (A) Model of extra-GC tangent fate trajectories leading to additional phenotypes observed from LCL scRNA-seq data. Proposed triggers associated with each trajectory are annotated in blue. (B) Differentially expressed markers defining tangent phenotypes in LCLs (PB/PC = plasmablasts/plasma cells, quiescent/arrested cells, and lytic reactivation).
high basal proliferation rate (~24h doubling time), LCLs stimulated with IL-21 (with or without R848) exhibited accelerated proliferation and higher cell densities than controls within three days of treatment (n = 3, IL-21 vs DMSO p = 0.04; R848 + IL-21 vs. DMSO p = 0.016, two-tailed paired Welch’s t-test) (Figure 6D). The most prominent response we observed in stimulated LCLs was a marked reduction in CD23 (FCER2) expression, with the greatest decrease observed in IL-21 and R848 + IL-21-treated LCLs (IL-21 vs. DMSO p = 0.00021; IL-21 + R848 vs. DMSO p = 3.51x10^{-5}, two-tailed Welch’s t-test of CD23 distribution geometric means, n = 4) (Figure 6E, S7A). IL-21 and R848 stimulation also led to modest increases in the percentage of IgD-/CD27- (double-negative, DN) B cells relative to the control treatment (Figure 6F). Based on prior studies on stimulated atMBC differentiation and the pathogenicity of atMBC-derived plasmablasts (PBs) (12, 101, 150), we assayed...
the frequency of DN-derived PBs (defined as IgD-/CD27-/CD23-/CD38+/CD138(SDC1)+ cells) across LCL treatment groups. Using a sequential gating strategy, we observed higher frequencies of autoimmune-associated DN-derived PBs in LCLs treated with R848, IL-21, or R848+IL-21 relative to control LCLs, although these differences were not statistically significant. R848-treated LCLs (n = 3, 2.74 ± 0.93 fold more DN PBs vs. DMSO, two-tailed Welch’s t-test p = 0.08) had the highest frequency of DN-derived PBs (Figure 6G). Intriguingly, even unstimulated LCLs exhibited a significantly higher DN B cell frequency than uninfected peripheral B cells (74.9 ± 2.3% vs. 17.8 ± 1.3%, Welch’s t-test p = 0.008, n = 2), though these data do not represent donor-matched measurements (Figure S7B).

Proliferative CXCR3+ B cells are induced during de novo EBV infection

In addition to studying atMBC responses to stimuli in the context of established EBV latency, we asked whether de novo infection itself was sufficient to induce an atMBC-like phenotype. Specifically, recent work has reported an association between EBV infection and a neuroinvasive, pathogenic subset of T-bet+/CXCR3+ B cells identified within clinically isolated syndrome (CIS)/multiple sclerosis (MS) patients (151–153). To address this possibility, we performed time-resolved FACS experiments to determine whether CXCR3-expressing B cells were induced during the early stages of EBV infection. Infection of enriched peripheral blood B cells with the B95-8 EBV strain led to the development of a CD19+/CXCR3+/CD11c+ cell population within five days in vitro (Figures 7A-D, Figure S7C). After the first several days of infection, the percentage of CD19+/CXCR3+/CD11c+ that also expressed FCRL4 (an inhibitory receptor and EBV-induced host biomarker (122)) progressively increased (Figures 7A-D, third column). In single cells gated from two biological donors, the average frequency of CD19+/CXCR3+/CD11c+/FCRL4+ gated cells was 38.6 ± 15.7% at day 8 post-infection compared to 9.8 ± 3.2% of cells prior to infection (n = 2 LCLs, two-tailed Welch’s t-test p = 0.224). Notably, CD19+/CXCR3+/CD11c+/FCRL4+ cells underwent EBV-induced hyperproliferation and exhibited similar cell division profiles relative to the total CD19+ population based on cell tracking dye dilution over time (Figure 7E, S7C).

Discussion

Single-cell technologies provide powerful means to examine how EBV manipulates host cell programming to achieve viral replication. In the present work, we have used these methods to identify and study cellular diversity that arises via EBV infection.
Our findings yield new insight into dynamic virus-driven cell heterogeneity within lymphoma models and provide a framework to explore the functional significance of EBV infection within T-bet+ atypical B cells that may promote pathogenic features of this cellular niche in autoimmunity and chronic infection.

Extensive work by Thorley-Lawson and colleagues has supported the development of the Germinal Center (GC) model of EBV infection, which accounts for an in vivo route to EBV latency establishment within the peripheral MBC reservoir (41, 42, 56, 154). Subsequent studies by our lab and others (24, 32, 43, 122, 155–157) have provided refinements to the GC model including the correspondence of distinct viral latency gene expression programs with the stages of B cell response to antigen (Figure 8A). These include a pre-latent phase (mimicking pre-GC B cells); Latency Iib, during which all six EBNA2s are expressed and cells rapidly proliferate (GC DZ-like); Latency III, in which the LMPs are additionally expressed and promote cell survival (GC LZ-like); and Latency IIa, in which EBNA expression is downregulated concomitant with GC exit. At a high level, the GC model underscores the capacity of EBV to induce programmed B cell responses in the absence of BCR-cognate antigen and direct T_H cell engagement. However, the potent immunogenicity of the latency gene products and prevalence of EBV-specific T cells provides a selective pressure for infected MBCs to adopt restricted latency

---

**FIGURE 8**

Models of EBV-driven germinal center dynamics and possible roles in priming of T-bet+ atypical MBC pathogenesis. (A) The Germinal Center (GC) model of EBV infection in vivo. (B) A model of perpetual GC dynamics within EBV-immortalized B cells in vitro. (C) Models of atMBC behaviors associated with pathogenic autoimmunity and potential EBV-induced priming of these responses.
in vivo, in which only the episome-maintaining EBNA1 and non-coding EBERs and miRNAs (Latency I) or EBERs and miRNAs only (Latency 0) are expressed.

By contrast, T cell-mediated suppression of EBV+ MBCs may be attenuated in patients with compromised or suppressed immune systems. Unchecked proliferation of EBV+ MBCs in these contexts can lead to the development of virus-associated Diffuse Large B Cell Lymphomas (DLBCLs) including post-transplant lymphoproliferative disease (PTLD) in organ transplant recipients (75). In this regard, EBV-immortalized in vitro systems provide useful models to study virus-driven lymphomagenesis associated with these diseases. We found that distinct subsets of B cells within LCLs undergo dynamic interconversion to sustain equilibrium distributions of activated and differentiated states. Critically, memory cells (ICAM-1Lo/CD27Hi) did not constitute a dead end for replication but could instead develop into the activated phenotype (ICAM-1Hi/CD27Lo) with greater proliferative potential. We further utilized pseudotime analysis of scRNA-seq to demonstrate that these in vitro dynamics are part of a perpetual cycle of B cell GC reaction engagement (Figure 8B). This perpetual GC was conserved across normal B cells infected with different strains of EBV (B95-8, M81). Another recent study (158) developed additional scRNA-seq data from LCLs generated with Type 1 Mutu and Type 2 BL5 EBV strains. We did not conduct a formal analysis of these datasets, however the conservation of GC-like states in cells immortalized by these strains is clear [MBCs = clusters 4, 5; AP-eMBC = cluster 2; Act. LZ = cluster 1; cycling DZ = clusters 0, 3, and 7; plasmablasts = cluster 6; lytic and pre-lytic cells = clusters 8, 9, and 10 – refer to Figure 11 in Bristol et al. (158)].

Our data demonstrate that EBV mediates B cell activation and subsequent differentiation via GC-like dynamics. Virus-induced simulation of GC transcriptional programs and biomarkers is especially noteworthy since EBV strongly suppresses the expression and functions of the master transcriptional regulator of the germinal center, BCL6 (59, 136, 159). The ability of EBV infection to phenocopy elements of the GC reaction in the absence of BCL6 may be promoted at least partially by virus-induced epigenetic alterations that parallel centrocyte (LZ B cell) cis and trans regulatory control at the BCL2A1 locus, which we have recently reported (160). While in vitro EBV-induced LCL formation is well understood in the context of the functions of viral oncoproteins, it is intriguing to consider the contributions of B cell-intrinsic biology to immortalization in culture. Such aspects include the continuous engagement of GC B cell transcriptional programs and, more generally, the retained cellular plasticity that underlies adaptive immune responses and memory. While important facets of GC B cells and their functions are evident within LCLs, our data indicate that there are discrepancies not only between LCLs and tonsillar GCs but also with respect to classically defined DLBCL subtypes. Specifically, cells within LCLs – at least those derived from unsorted peripheral B cells – can display co-expression of genes characteristic of both GCB-DLBCLs and ABC-DLBCLs. In this context, future work is needed to assess whether B cells at different developmental or functional stages that are transformed by EBV might retain cell of origin characteristics. Whether the heterogeneity and state transitions of the in vitro perpetual GC are defining features of EBV+ lymphomas in vivo is currently unclear, however it has been found that GC dynamics are desynchronized in Follicular Lymphoma (FL) (7), which is rarely EBV+. Thus, future studies that examine clinical samples will be essential to determine whether B cells with unregulated GC dynamics or even spatial organization are present across a spectrum of EBV+ lymphoid malignancies.

The exquisite adaptation of EBV to modulate host cell programs highlights the importance of using single-cell approaches to resolve consequences of viral infection within particular B cell subsets. This is especially relevant for T-bet+ atMBC pools, which are enriched with autoreactive clones (161, 162). Pathogenic atMBC expansion (and differentiation to plasma cells) elicited by cytokines and innate stimuli constitutes a common feature of chronic infection with HIV (106) and Plasmodium falciparum (105) and an array of diseases of autoimmunity or immune dysregulation including multiple sclerosis (MS) (10), systemic lupus erythematosus (SLE) (12), rheumatoid arthritis (RA) (146), and primary Sjögren’s Syndrome (pSS) (163). Notably, associations with EBV have been identified in many of the same diseases in which atMBCs are dysfunctional. Thus, our scRNA-seq evidence for atMBCs within LCLs and corresponding tangent fate trajectories including plasmablast formation prompted us to use LCLs as a model system to study possible roles of latent EBV infection in aspects of B cell-mediated autoimmunity. We also examined the potential role that de novo EBV infection may play in promoting the development of CXCR3+ atMBCs identified in patients with MS. This interest was rooted in several distinct lines of evidence. First, we recently reported that de novo EBV infection within atMBCs (TBX21/T-bet+, ITGAX/CD11c+, FCRL4+, FCRL5+) induced elevated expression of inflammatory mediators and – unexpectedly – neuronal lineage genes involved in nervous system development and axon guidance (15). Second, there is strong etiological support for the importance of EBV seropositivity during late adolescence or early adulthood – but not childhood – in the development of MS (94–96). Paired with studies demonstrating the accumulation of T-bet+ atMBCs with age (100), we see a convergence of epidemiological and functional studies that implicates a pathogenic role for de novo EBV infection of atMBCs. Finally, recent reports by van Langelaar and colleagues have described an enriched subset of CXCR3+ neuroinvasive B cells associated with elevated EBV viral loads in MS patients (151, 152). Based on their findings, van
Langelaar et al. developed a model in which MS patient B cell engagement with a cognate T cell (CD40/CD40L and TCR/Ag-MHC class II recognition) in conjunction with IL-21 and especially IFNγ stimulation induces T-bet expression and subsequent CXCR3 upregulation (Figure 8C, left panel). In this model, CXCR3 promotes T-bet+ B cell migration from secondary lymphoid tissue to the brain via the periphery, consistent with this chemokine receptor's essential role in T cell (164) and ASC (165) neuroinvasion. Additional innate stimulation via TLR agonism then mediates the conversion of T-bet+ B cells to antibody-secreting cells.

In the latent infection context, EBV+ atMBCs may develop from EBV+ MBCs that are subsequently stimulated to express T-bet by IFNγ secreted by proximal T cells, possibly in response to unrelated infections. These EBV+ atMBCs may then be primed for differentiation in response to IL-21 and/or TLR7 agonism without cognate engagement with T cells (Figure 8C, middle panel). This scenario is conceivable for infected B cells that express both LMP1, which mediates CD40 signaling, and LMP2A, which downregulates MHC class II expression and mimics a constitutively activated BCR. The observed significant enrichment of an autoimmune-associated DN B cell phenotype (CD19+IgD-/CD27+) in LCLs versus uninfected peripheral B cells provides in vitro evidence that infected atMBCs may develop in the course of EBV latency establishment. We also assayed the effects of TLR7 agonism and IL-21 stimulation of LCLs on cell proliferation and the induction of plasma cells, both of which are characteristics of atMBCs in autoimmunity. Treatment of LCLs with IL-21 (with or without R848) led to marked reduction of CD23 expression. This response is particularly notable, given that CD23+ GC B cells from human tonsils have been identified as precursors to plasma cells (166) and that expansion and differentiation of CD23- DN B cells has been observed in SLE (145, 167, 168). Treatment with IL-21 or R848 + IL-21 also yielded modest but significant increases in LCL growth, consistent with responses of atMBC niches including DN B cells to these stimuli (149). In this regard, it is noteworthy that TBX21(T-bet)+ atMBCs in LCL scRNA-seq data consistently exhibited elevated expression of IL21R and TLR7, inhibitory BCR co-receptors, and anti-GC AP-eMBC signatures. These facets are consistent with defined characteristics of atMBCs common to chronic infections and autoimmunity including BCR hyposensitivity (anergy) and extracellular activation by innate stimuli (11, 169). Whether antigen-independent B cell activation enacted through EBV infection predisposes poor affinity maturation – another hallmark of autoreactive atMBCs – remains to be studied. In contrast to the robustness of CD23 downregulation upon IL-21 treatment of LCLs, we observed only subtle increases (not statistically significant) in the frequency of EBV+ IgD+/CD27+/CD23+/CD38+/CD138+ cells relative to controls. We speculate that the effect of these stimulations on cell growth may be muted in LCL models due to their high basal rates of proliferation. Moreover, plasma cell formation within LCL populations is generally uncommon, since viral EBNA3A and EBNA3C proteins suppress plasma cell differentiation within roughly two weeks of latency establishment via epigenetic modifications of the PRDM1 (Blimp-1) and CDKN2C (p18INK4C) loci (59). These viral countermeasures to circumvent terminal differentiation likely contribute to the minimal increase in DN-derived PBs upon stimulation despite the significant downregulation of CD23. Thus, we emphasize that LCLs without additional experimental modifications may have limited utility for studies of EBV+ MBC responses to stimuli in the context of autoimmunity. The fact that plasmablasts arise at all within LCLs raises questions as to what mechanisms might enable EBV+ B cells to overcome EBNA3-mediated epigenetic suppression of plasma cell formation – and whether they occur within EBV+ atMBCs in vivo.

In the de novo infection context, we found that EBV increases CXCR3 (as well as CD11c and FCR14) expression on peripheral B cells. Moreover, EBV+ CD19+/CXCR3+/CD11c+/FCRL4+ cells and parental CD19+ populations proliferated to a similar extent in response to infection. Consistent with these findings, EBV infection of existing T-bet+ atMBCs may provide a stimulus that facilitates the reported expansion and neuroinvasive phenotype of CXCR3+ atMBCs (Figure 8C, right panel). As EBV virion entry is known to upregulate TLR7 expression and pathway sensitivity (170), it is possible that newly infected atMBCs may be primed for differentiation to plasmablasts triggered by recognition of exogenous nucleic acids from EBV itself or other infectious agents. In this case, it is alluring to speculate that differentiation of recently infected atMBCs upon innate stimulation may rapidly promote the initiation of viral reactivation through XBP1 and PRDM1 transactivation of the master EBV lytic regulator BZLF1.

Echoing the distinctions between the GC model of infection and conventional B cell specific immunity, EBV may prime atMBCs for pathogenic responses in de novo infection and/or atMBCs derived from latently infected MBCs without explicit requirements for antigen-specific activation or direct T cell engagement. While the data and models presented here provide a starting point to dissect viral involvement in aspects of atMBC-mediated autoimmunity, this is currently a field with many more open questions than definitive answers. Future functional and mechanistic studies are clearly required to address these questions and test the proposed models. We expect the presented single-cell analysis and experiments as well as future high-resolution studies will be essential to
dissect EBV-mediated dysregulation of B cell compartments in lymphoproliferative malignancies, chronic infections, and autoimmune diseases.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/geo/, GSE158275; https://www.ncbi.nlm.nih.gov/geo/, GSE126321; https://www.ncbi.nlm.nih.gov/geo/, GSE159674

Ethics statement

The primary B cells and LCLs used in this study were prepared from buffy coats obtained through the Gulf Coast Regional Blood Center from anonymous donors. These biological samples lacked all HIPAA identifiers and PHI and the studies were thus considered as non-human subjects research and approved by a Duke University IRB (eIRB #Pro00006262).

Author contributions

ES and NR-V share first authorship of this work. ES, NR-V, GH, and ML contributed to the conception and design of the study. ES, NR-V, and GH performed the experiments and acquired the data. ES, NR-V, GH, and ML analyzed the data. ES and NR-V wrote the initial draft of the manuscript. GH wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by NIH funding from the National Institute of Dental and Craniofacial Research (NIDCR, #R01DE025994). ES wishes to acknowledge support from the Duke University Viral Oncology Training Grant (NIH, #T32CA009111) and an American Cancer Society postdoctoral fellowship (ACS, PF-21-084-01-DMC).

Acknowledgments

We would like to thank the Luftig Lab members – especially Katherine Willard – for thoughtful feedback during the development of this study and in drafting the manuscript and figures. We also wish to thank the anonymous blood donors whose samples made this work possible.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1001145/full#supplementary-material

SUPPLEMENTARY FIGURE 1
Additional LCL replicates for FACS populations and sorting. (A) Biological replicates for ICAM-1/CD27 FACS staining. (B) Phenotype composition in LCLs is dependent on cell density. (C) Biological replicates for time-resolved assays of ICAM-1 and CD27 in sorted LCL fractions. Top row in each replicate: ICAM-1Lo/CD27Lo. Middle row in each replicate: ICAM-1Hi/CD27Lo. Bottom row in each replicate: ICAM-1Lo/CD27Hi. The box inset depicts a technical artifact arising from FACS buffer contamination that affected the observed CD27/ICAM1 distribution from days 3-5. (D) Replicate experiments performed with increased gating stringency to exclude the possibility of phenotype contamination leading to the observed recovery of parental line distributions.

SUPPLEMENTARY FIGURE 2
Additional marker genes in DZ and AP-eMBC states. (A) Key marker genes in cycling (DZ-like) cells across LCLs. Data are presented for three LCLs generated in-house (left column) and commercially available LCLs (GM12878, middle; GM18502, right) originally reported by Osorio et al (112). (B) Key marker genes in AP-eMBC cells across LCLs. Data are presented for three LCLs generated in-house (left column) and commercially available LCLs (GM12878, middle column; GM18502, right column) originally reported by Osorio et al (112).

SUPPLEMENTARY FIGURE 3
GC B cell and DLBCL gene expression in LCLs and tonsils. (A) GC B cell biomarker scoring in tonsil and LCL scRNA-seq datasets (left column). Gene module correlations between Classic GC, DZ, DZ cycling, and LZ markers (middle column). Correlation between GCB-DLBCL and ABC-DLBCL module scores. (Classic GC module = BCL6, LMO2, MYBL1, MME, SERPINA9, GCSAM, DGKD, IL4R, SPIL, SHB2, ALOX5, BCL7A, LCK, OGG1, DZ module = AICDA, FOXO1, CXCR4, AURKC, IL2RB, LZ module = TCF3, EZH2, CCND3, E2F2, TP53, PLK4, BRCAl, LZ module = NFKB1, NFKB2, BCL6, BCL2, CD86, BCL2A1, EBI3, CD40, CR2, MIR155HG, ACKR3, MYO1C, MYC) (B) Co-expression of canonical GC
Supplementary Figure 4

Distinct CD27⁺ subsets and key marker genes in plasma cells across LCLs. (A) UMAP and upset plots of CD27 co-expression with markers of pre-GC early activation (CCR6, post-GC memory B cells/pre-plasmablasts (CD38, PRDM1)), and late ASCs (SDC3) across LCLs. Upset plots depict cells with co-expression at levels greater than or equal to the 25th percentile for each gene's respective distribution across the given dataset. (B) Top markers within late plasma cells (ASCs). Data are presented for three LCLs generated in-house (left column) and commercially available LCLs (GM12878, middle column; GM18502, right column) originally reported by Osorio et al (112).

Supplementary Figure 5

Key marker genes in lytic cells across LCLs. Data from differentially expressed genes of interest are presented for three LCLs generated in-house.

Supplementary Figure 6

Expression signature of atMBCs within LCLs. (A) Pearson R correlations for single-cell co-expression of the atMBC markers TBX21, FCRL5, and CXCR3 in LCLs. (B) Data from differentially expressed genes of interest are presented for three LCLs generated in-house and commercially available LCLs (GM12878, GM18502) originally reported by Osorio et al (112). Three of five LCL datasets contain cells consistent with atMBCs exhibiting elevated expression of key receptors that mediate atMBC responses to stimuli in addition to AP-eMBC characteristics (identified by green circles). Cells with AP-eMBC characteristics but lacking definitive atMBC gene expression in the remaining two LCLs are also highlighted (blue circles).

Supplementary Figure 7

Additional replicates for FACS studies of EBV-associated autoimmune phenotypes in LCLs and de novo infection. (A) FACS replicates for CD23 (FCER2) downregulation upon stimulation with R848 and/or IL-21. (B) FACS staining of IgD and CD27 in uninfected peripheral B cells to identify putative double negative (DN) B cell frequencies. Samples were prepared via B cell enrichment (negative isolation) from PBCMs. Data are presented for two donors. (C) Biological replicate for cell proliferation and CXCR3, CD11c, FCRL4 staining in de novo infection experiments.

References

1. King HW, Orban N, Riches JC, Clear AJ, Barnes G, Teichmann SA, et al. Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics. Sci Immunol (2021) 6(56):eabe6291. doi: 10.1126/sciimmunol.abf6291

2. Ranzoni AM, Tangherloni A, Berest I, Riva SG, Myers B, Strzelecka PM, et al. Integrative single-cell RNA-seq and ATAC-Seq analysis of human developmental hematopoiesis. Cell Stem Cell (2021) 28(3):472–87.e7. doi: 10.1016/j.stem.2020.11.015

3. Glaros V, Rauschmeier R, Artemov AV, Reinhardt A, Ols S, Emmanoulidou A, et al. Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response. Immunity (2021) 54(9):2005–23.e10. doi: 10.1016/j.immuni.2021.08.017

4. Stewart A, Ng JC-F, Vallis G, Tsolikova V, Dunn-Walters DK. Single-cell transcriptomic analyses define distinct peripheral B cell subsets and discrete development pathways. Front Immunol (2021) 12:602539. doi: 10.3389/fimmu.2021.602539

5. Maddison E, Willrey-Clark A, Miragaia R, Saeb-Parsy K, Mahbubani K, et al. A pathogenic and clonally expanded B cell transcriptome in early multiple sclerosis. Proc Natl Acad Sci U S A (2021) 118(1):1–14. doi: 10.1073/pnas.2008533117

6. Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of human B cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell (2021) 39(1):1422–37. doi: 10.1016/j.ccell.2021.08.011

7. Sabatino JJ, et al. A pathogenic and clonally expanded B cell transcriptome in early multiple sclerosis. Proc Natl Acad Sci U S A (2021) 118(1):1–14. doi: 10.1073/pnas.2008533117

8. Andor N, Simonds EF, Czerwinski DK, Chen J, Grimes SM, Wood-Bouwens J, et al. The landscape of human B cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell (2021) 39(1):1422–37. doi: 10.1016/j.ccell.2021.08.011

9. Holmes AB, Corinaldesi C, Shen Q, Kumar R, Compagno N, Wang Z, et al. Shared transcriptional profiles of atypical B cells suggest common drivers of expansion and function in malaria, HIV, and autoimmunity. Sci Adv (2021) 7(12):eabc6834

10. Wang S, Wang J, Kumar V, Karmell JL, Naiman B, Gross PS, et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD3⁺B cells in LCLs. J Exp Med (2021) 219(9):1013–28. doi: 10.1084/jem.202002483

11. Madissoon E, Wilbrey-Clark A, Miragaia R, Saeb-Parsy K, Mahbubani K, et al. A pathogenic and clonally expanded B cell transcriptome in early multiple sclerosis. Proc Natl Acad Sci U S A (2021) 118(1):1–14. doi: 10.1073/pnas.2008533117

12. Scharer CD, Patterson DG, Mi T, Price MJ, Hicks SL, Boss JM. Antibody-secreting cell destiny emerges during the initial stages of B-cell activation. Nat Commun (2020) 11(1):1–14. doi: 10.1038/s41467-020-17798-x

13. Woydell WT, Smolkin RM, Bellcheva KT, Mendosa A, Michaels AJ, Cols M, et al. Temporal dynamics of persistent germinal centers and memory B cell differentiation following respiratory virus infection. Cell Rep (2021) 37(6):109961. doi: 10.1016/j.celrep.2021.109961

14. Cols M, Smolkin RM, Bellcheva KT, Mendosa A, Michaels AJ, Cols M, et al. Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection. Cell Rep (2022) 48(9):111266.

15. Rickinson A, Kieff E. Epstein-Barr virus. Philadelphia: Fields Virology, Lippincott Williams & Wilkins (2007). 7655–790 p.

16. Nemez GW, McNaughton ME, Cooper NR. Binding of monoclonal antibody to the Epstein-Barr virus (EBV) CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol (1985) 135(3):3088–73.
Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late EBNA3C directs recruitment of RBPJ (CBF1) to chromatin during the process of based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding effect on the promoter of the cell gene CD21.

EBNA2 drives formation of new chromosome binding sites and target genes for B-cell master regulatory transcription factors RBP-j chromosomal DNA in non-virus-producing cells.

EBNA2 and correlates with the B-cell activation phenotype. factor AML-2 (RUNX3, CBF(α)-3) is induced by Epstein-Barr virus EBNA-2 repression of p16INK4A by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP.

doi: 10.1128/jvi.72.10.7900-7908.1998

Fish K, Connolly F, Shaffer AL, Yi J, Pan K-T, Scheich S, et al. Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. Prog Natl Acad Sci USA (2001) 98(3):1296-307. doi:10.1073/pnas.79.4.1296-1307.2000

Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol (2007) 81(14):7363-70. doi:10.1128/jvi.00154-07

Sun CC, Thorley-Lawson DA. Plasma cell-specific transcription factor XBP-1 binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol (2007) 81(24):13566-77. doi:10.1128/jvi.01055-07
64. Speck SH, Chatila T, Flemington E. Reactivation of Epstein-Barr virus replication and function of the RLF1 gene. Trends Microbiol (1997) 5(10):399–405. doi:10.1016/S0966-842X(97)90112-9 65. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. *New Engl J Med* (2004) 350(13):1328–37. doi:10.1056/NEJMra032215 66. Niedobitek G, Meru N, Delecluse HJ. Epstein-Barr virus infection and human malignancies. *Int J Exp Pathol* (2001) 82(3):149–70. doi:10.1111/j.1349-7266.2001.190.x 67. Epstein M, Achong B, Barry Y. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. *Lancet* (1964) 283(7335):702–3. doi:10.1016/S0140-6736(64)91524-7 68. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle G, Henle W, Clifford P, et al. Epstein-Barr virus in Burkitt’s lymphoma and nasopharyngeal carcinoma. *Natl Cancer Inst Monogr* (1979) 28:1056–8. doi:10.1093/ncim/99.11.2190 69. Moormann AM, Snider CJ, Chelimo K. The company malaria keeps: how coinfection with Epstein-Barr virus leads to endemic Burkitt lymphoma. *Curr Opin Infect Dis* (2011) 24(5):435. doi:10.1097/QCO.0b013e328349a4cf 70. Niedobitek G, Agathanggelou A, Rowe M, Jones E, Jones D, Turyaguma P, et al. Heterogeneous expression of Epstein-Barr virus latency proteins in endemic Burkitt’s lymphoma. *Blood J Am Soc Hematol* (1995) 85(7):2049–55. doi:10.1182/blood.v85.7.2049 71. Carbone A, Ghiglioni A, Larroca LM, Antinori A, Falini B, Tirielli U, et al. Human gammaherpesvirus-associated Hodgkin’s disease derives from post-germinal center B cells. *Blood J Am Soc Hematol* (1999) 93(7):2319–26. doi:10.1182/blood.V93.7.2319 72. Cohen JJ. Epstein-Barr virus infection. *New Engl J Med* (2000) 343(7):481–5. doi:10.1056/NEJM200007133430707 73. Carbone A, Cesariano E, Spina M, Ghiglioni A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. *Blood J Am Soc Hematol* (2009) 113(6):1213–24. doi:10.1182/blood-2008-09-180315 74. Gregg K, Miller R, Dogan A. HIV infection and lymphoma. *J Clin Pathol* (2007) 60(12):1365–72. doi:10.1136/jcp.2007.051953 75. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. *Transplantation* (1999) 68(10):1517–25. 76. Rowe M, Young L, Crocker J, Stokes H, Henderson S, Rickinson A. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implication for the pathogenesis of EBV-positive lymphomas in man. *J Exp Med* (1991) 173(1):147–58. doi:10.1084/jem.173.1.147 77. Cohen JJ, Fauci AS, Varvchis H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. *Sci Transl Med* (2011) 3(107):307567–67. doi:10.1126/scitranslmed.3002878 78. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. *Nat Rev Cancer* (2004) 4(10):757–68. doi:10.1038/nrc1452 79. Sun K, Jia K, Lv H, Wang S-Q, Wu Y, Lei H, et al. EBV-positive gastric cancer: current knowledge and future perspectives. *Front Oncol* (2020) 10:583463. doi:10.3389/fonc.2020.583463 80. Larsen M, Sauce D, Deback C, Arnaud L, Mathian A, Miyara M, et al. Exhausted cytotoxic expression of Epstein-Barr virus latent protein 3a in human lymphomas. *PLoS Pathog* (2011) 7(10):e1002328. doi:10.1371/journal.ppat.1002328 81. Poole BD, Templeton AK, Guthridge JM, Brown EL, Harley JB, James JA. Aberrant Epstein-Barr virus viral infection in systemic lupus erythematosus. *Autoimmun Rev* (2009) 8(6):337–42. doi:10.1016/j.autrev.2008.12.008 82. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. *J Immunol* (2005) 174(11):6599–607. doi:10.4049/jimmunol.174.11.6599 83. Kang I, Quan T, Nolasco H, Park S-H, Hong MS, Crouch J, et al. Overexpression of T-bet in HIV infection is associated with accumulation of B-cells outside germinal centers and poor affinity maturation. *Sci Transl Med* (2019) 11(520):eaax0904. doi:10.1126/scitranslmed.aax0904 84. Rubtsova K, Rubtsov AV, Thurman JM, Mennonna JM, Kappler JW, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. *Blood* (2011) 118(5):1305–15. doi:10.1182/blood-2011-03.314652 85. Johnson JL, Rosenthal RL, Knox J, Myles A, Naradikian MS, Madje J, et al. The transcription factor T-bet resolves memory B cell subsets with distinct tissue distributions and antibody specificities in mice and humans. *Immunity* (2020) 52(5):842–55. doi:10.1016/j.immunity.2020.03.020 86. Austin JW, Buckner CM, Kardava L, Wang W, Zhang X, Melson VA, et al. Overexpression of T-bet in HIV infection is associated with accumulation of B-cells outside germinal centers and poor affinity maturation. *Sci Transl Med* (2019) 11(520):eaax0904. doi:10.1126/scitranslmed.aax0904 87. Rubtsova K, Rubtsov AV, Thurman JM, Mennonna JM, Kappler JW, Marrack P. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. *J Clin Invest* (2017) 127(4):1932–40. doi:10.1172/JCI92150 88. Rubtsova K, Marrack P, Rubtsov AV. TLR7, IFNγ and T-bet: Their roles in the development of ABCs in female-biased autoimmunity. *Cell Immunol* (2015) 294(2):80–3. doi:10.1016/j.cellimm.2014.12.002 89. Weiss GE, Crompton PD, Li S, Walsh LA, Moore S, Traore B, et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. *J Immunol* (2009) 183(5):2176–82. doi:10.4049/jimmunol.0901297 90. Moir S, Ho J, Malalipina A, Wang W, DiPoto AC, O’Shea MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected virologic individuals. *J Exp Med* (2008) 205(8):1787–805. doi:10.1084/jem.20072683 91. Hafez AY, Luftig MA. Characterization of the EBV-induced persistent DNA damage response. *Viruses* (2017) 9(12):366. doi:10.3390/v9120366 92. McFadden K, Hafez AY, Kisholt R, Messinger J, Nikitin PA, Rathenell JC, et al. Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. *Proc Natl Acad Sci* (2016) 113(6):E782–E90. doi:10.1073/pnas.1517141113 93. Nikitin PA, Price AM, McFadden K, Yan CM, Luftig MA. Mitogen-induced B-cell proliferation activates CD28-dependent G1/S cell cycle arrest. *PLoS One* (2014) 9(1):e87229. doi:10.1371/journal.pone.0087229 94. Forte E, Luftig MA. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. *J Virol* (2009) 83(9):2491–9. doi:10.1128/jvi.01681-08
156. Jochum S, Ruiss R, Moosmann A, Hammerschmidt W, Zeidler R. RNAs in Epstein-Barr virions control early steps of infection. *Proc Natl Acad Sci* (2012) 109 (21):E1396–404. doi: 10.1073/pnas.1115906109

157. Mrozek-Gorska P, Buschle A, Pich D, Schwarzmayr T, Fechtner R, Scialdone A, et al. Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. *Proc Natl Acad Sci* (2019) 116 (32):16046–55. doi: 10.1073/pnas.1901314116

158. Bristol JA, Brand J, Ohashi M, Eichelberg MR, Casco A, Nelson SE, et al. Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. *PloS Pathogens* (2022) 18(4):e1010453. doi: 10.1371/journal.ppat.1010453

159. Boccellato F, Anastasiadou E, Rosato P, Kempkes B, Frati L, Faggioni A, et al. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin’s lymphoma cells. *J Virol* (2007) 81(5):2274–82. doi: 10.1128/jvi.01822-06

160. Dai J, Heckenberg E, Song L, Crawford GE, Luftig MA. Epstein-Barr virus promotes survival through germinal center light zone chromatin architecture. *bioRxiv* (2020). doi: 10.1101/2020.10.22.350108

161. Naradikian MS, Hao Y, Cancro MP. Age-associated B cells: key mediators of both protective and autoreactive humoral responses. *Immuno Rev* (2016) 269 (1):118–29. doi: 10.1111/imr.12380

162. Rubtsova K, Rubtsov AV, Cancro MP, Marrack P. Age-associated B cells: a T-bet-dependent effector with roles in protective and pathogenic immunity. *J Immunol* (2015) 195(5):1933–7. doi: 10.4049/jimmunol.1501209

163. Verstappen GM, Ice JA, BootmA, H, Pringle S, Haake DE, de Lange K, et al. Gene expression profiling of epithelium-associated FcRL4+ B cells in primary Sjögren’s syndrome reveals a pathogenic signature. *J Autoimmun* (2020) 109:102439. doi: 10.1016/j.jaut.2020.102439

164. Xu J, Neal LM, Ganguly A, Kolbe JL, Hargarten JC, Elsegeiny W, et al. Chemokine receptor CXCR3 is required for lethal brain Pathology but not pathogen clearance during cryptococcal meningoencephalitis. *Sci Adv* (2020) 6 (25):eaba2502. doi: 10.1126/sciadv.aba2502

165. Marques CP, Kaul P, Hinton DR, Hindinger C, Nutt SL, Ranseboff BM, et al. CXCR3-dependent plasma blast migration to the central nervous system during viral encephalomyelitis. *J Virol* (2011) 85(13):6136–47. doi: 10.1128/jvi.00202-11

166. Santamaria K, Desmots F, Leonard S, Caron G, Haas M, Delaloy C, et al. Committed Human CD23-Negative Light-Zone Germinal Center B Cells Delinate Transcriptional Program Supporting Plasma Cell Differentiation. *Front Immunol* (2021) 12:5142. doi: 10.3389/fimmu.2021.744573

167. Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. *Front Immunol* (2019) 10:2458. doi: 10.3389/fimmu.2019.02458

168. Schaser CD, Blachok EL, Mi T, Barwick BG, Jenks SA, Deguchi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. *Nat Immunol* (2019) 20(8):1071–82. doi: 10.1038/s41590-019-0419-9

169. Ambegaonkar AA, Holla P, Dizon BL, Sief H, Pierce SK. Atypical B cells in chronic infectious Dis and systemic autoimmunity: puzzles with many missing pieces. *Cure Open Immunol* (2022) 77:102227. doi: 10.1016/cx.immunol.2022.102227

170. Martin HJ, Lee JM, Walls D, Hayward SD. Manipulation of the toll like receptor 7 signaling pathway by Epstein-Barr virus. *J Virol* (2007) 81(18):9748–58. doi: 10.1128/jvi.01122-07